BioNTech Target of Unusually Large Options Trading (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) was the recipient of some unusual options trading on Monday. Stock traders acquired 1,989 call options on the stock. This is an increase of 31% compared to the average volume of 1,519 call options.

Analysts Set New Price Targets

Several brokerages recently commented on BNTX. BMO Capital Markets cut their price objective on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday. Canaccord Genuity Group reissued a “buy” rating and issued a $171.00 target price on shares of BioNTech in a research report on Thursday, March 21st. The Goldman Sachs Group reduced their price target on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. JPMorgan Chase & Co. dropped their price objective on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a report on Friday, March 22nd. Finally, HC Wainwright restated a “buy” rating and set a $107.00 target price on shares of BioNTech in a research report on Wednesday, April 17th. One research analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $118.27.

Institutional Trading of BioNTech

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its position in shares of BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after buying an additional 150 shares during the last quarter. CWM LLC grew its stake in BioNTech by 657.6% during the fourth quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after acquiring an additional 217 shares in the last quarter. Frazier Financial Advisors LLC bought a new stake in BioNTech in the 4th quarter valued at $30,000. Covestor Ltd purchased a new stake in BioNTech in the 3rd quarter worth $32,000. Finally, First Horizon Advisors Inc. purchased a new stake in BioNTech in the 4th quarter worth $38,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $90.88 on Wednesday. The company has a market capitalization of $21.60 billion, a P/E ratio of 22.06 and a beta of 0.25. BioNTech has a 1-year low of $85.21 and a 1-year high of $125.83. The firm’s 50 day simple moving average is $90.53 and its two-hundred day simple moving average is $95.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.64 by ($0.59). The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $2.04 billion. BioNTech had a return on equity of 4.60% and a net margin of 24.26%. Research analysts expect that BioNTech will post -1.74 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.